News Feed Search

Results for search query: 'pharmaceutical'

Page 1

Fagron Sterile Services US (FSS) Delivers Pharmaceutical Innovation In Sterile Topical L.E.T. Gel

Fagron Sterile Services US (FSS), a top-tier DEA and FDA-registered 503B Outsourcing Provider, produces reliable supply of high-quality sterile medications with cGMP compliant operations for patient-focused healthcare facilities across North America.

At this time, LET Gel from Fagron Sterile Services US, is the only Sterile Topical LET Gel on the market from a 503B Outsourcing Facility or compounding pharmacy.

FSS leveraged pharmaceutical expertise spanning three decades to quickly develop the first Sterile Topical LET Gel in the industry - listening to both customer needs and the FDA.

503B Outsourcing Facility innovates topical LET anesthetic gel to produce the first widely available sterile option.

Company supports patient safety; innovating topical anesthetic gel to produce the first widely available sterile option from a 503B Outsourcing Facility - hospital emergency rooms, urgent care centers, pediatric offices and healthcare providers will benefit - WICHITA, Kan., Oct. 20, 2020 /PRNewswire/ -- Fagron Sterile Services US (FSS), a leading 503B pharmaceutical outsourcing provider, today announced a new product innovation - the launch of the first sterile topical anesthetic LET Gel produced at scale through cGMP compliant operations.

published chemicals market finance
Image of article 'Otonomy Inc (NASDAQ:OTIC) Given Average Recommendation of “Buy” by Brokerages'

Otonomy Inc (NASDAQ:OTIC) Given Average Recommendation of “Buy” by Brokerages

Shares of Otonomy Inc (NASDAQ:OTIC) have earned a consensus recommendation of “Buy” from the six ratings firms that are currently covering the stock, MarketBeat reports.

Cambridge Investment Research Advisors Inc. boosted its position in shares of Otonomy by 30.1% during the 2nd quarter.

Cambridge Investment Research Advisors Inc. now owns 15,140 shares of the biopharmaceutical company’s stock worth $55,000 after acquiring an additional 3,500 shares in the last quarter.

Jacobs Levy Equity Management Inc. now owns 57,825 shares of the biopharmaceutical company’s stock valued at $209,000 after acquiring an additional 27,562 shares during the last quarter.

Schonfeld Strategic Advisors LLC now owns 169,971 shares of the biopharmaceutical company’s stock valued at $616,000 after acquiring an additional 141,800 shares during the last quarter.

published earnings business
Image of article 'Diversified Trust Co Sells 697 Shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA'

Diversified Trust Co Sells 697 Shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA

Diversified Trust Co reduced its position in Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) by 11.8% during the third quarter, according to its most recent 13F filing with the SEC.

SVB Leerink lifted their target price on Arena Pharmaceuticals from $73.00 to $91.00 and gave the company an “outperform” rating in a report on Thursday, August 6th.

Needham & Company LLC reaffirmed a “buy” rating and set a $70.00 target price on shares of Arena Pharmaceuticals in a report on Thursday, August 6th.

Wells Fargo & Company lifted their target price on Arena Pharmaceuticals from $60.00 to $78.00 and gave the company an “overweight” rating in a report on Thursday, August 6th.

In other Arena Pharmaceuticals news, EVP Robert Lisicki sold 30,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 4th.

published earnings business

Retrophin (NASDAQ:RTRX) Rating Increased to Buy at BidaskClub

Jacobs Levy Equity Management Inc. boosted its holdings in shares of Retrophin by 14.1% in the second quarter.

Jacobs Levy Equity Management Inc. now owns 684,246 shares of the biopharmaceutical company’s stock worth $13,965,000 after acquiring an additional 84,355 shares during the period.

Nuveen Asset Management LLC now owns 595,533 shares of the biopharmaceutical company’s stock worth $12,155,000 after acquiring an additional 34,000 shares during the period.

Charles Schwab Investment Management Inc. now owns 403,354 shares of the biopharmaceutical company’s stock worth $8,233,000 after buying an additional 57,292 shares in the last quarter.

Point72 Asset Management L.P. now owns 386,126 shares of the biopharmaceutical company’s stock worth $7,881,000 after buying an additional 82,746 shares in the last quarter.

published earnings business

Agios falls after pulling European marketing application for Tibsovo (NASDAQ:AGIO

Based on feedback from the European Medicine Agency’s Committee for Medicinal Products for Human Use (CHMP), Agios Pharmaceuticals (NASDAQ:AGIO) has decided to withdraw its European application seeking approval for Tibsovo (ivosidenib tablets) for the treatment of relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-1 (IDH1) mutation.

CHMP said that data from the company’s single arm, uncontrolled Phase 1 study do not sufficiently support a positive benefit-risk balance for the proposed indication.

Tibsovo is currently approved in the U.S. for certain IDH1-positive leukemia patients.

published lobbying business finance

Opthea Announces Pricing of Initial Public Offering in the United States

16, 2020 (GLOBE NEWSWIRE) -- Opthea Limited ((ASX:OPT, NASDAQ:OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progressive retinal diseases, today announces the pricing of its initial public offering in the United States (the "Offering") of 8,563,300 American Depositary Shares ("ADS"), representing 68,506,400 ordinary shares, at an initial public offering price of US$13.50 per ADS, before underwriting discounts and commissions.

The Company has also granted the underwriters a 30-day option to purchase up to an additional 1,425,000 ADSs at the initial public offering price per ADS less underwriting discounts and commissions.

Forward-looking Statements Certain statements in this announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, regarding the Company's business as well as the proposed Offering.

Any statement describing Company goals, expectations, intentions or beliefs, including as they relate to the proposed Offering and its expected closing, is a forward-looking statement and should be considered an at-risk statement.

Such statements are subject to certain risks and uncertainties, including market conditions, the satisfaction of customary closing conditions relating to the Offering and the impact of general economic, industry or political conditions in Australia, the United States or internationally.

published chemicals finance
Image of article 'Aslan Pharma to develop ASLAN003 for autoimmune diseases (NASDAQ:ASLN'

Aslan Pharma to develop ASLAN003 for autoimmune diseases (NASDAQ:ASLN

ASLAN Pharmaceuticals (NASDAQ:ASLN) plans to develop ASLAN003, its next-generation inhibitor of dihydroorotate dehydrogenase (DHODH), in autoimmune conditions such as multiple sclerosis (MS).

Based on the specificity, potency and favourable safety profile identified in earlier clinical studies, the company believes ASLAN003 is a promising candidate for development in MS and other autoimmune diseases.

The company expects to share further details in early 2021.

ASLAN003 has been shown to be more than 30 times more potent at inhibiting the DHODH enzyme than teriflunomide.

published chemicals business finance
Image of article 'US regulators approve 1st treatment for Ebola virus'

US regulators approve 1st treatment for Ebola virus

On Wednesday, the U.S. Food and Drug Administration said it has approved the drug for treating Ebola in both adults and children.

Survival was significantly better in study participants given Regeneron's Inmazeb or a second experimental drug.

The Food and Drug Administration OK'd the drug developed by Regeneron Pharmaceuticals for treating adults and children with the Zaire Ebola virus strain, the most deadly of six known types.

(Regeneron via AP) U.S. regulators Wednesday approved the first drug for the treatment of Ebola.

On Wednesday, the U.S. Food and Drug Administration said it has approved the drug for treating Ebola in both adults and children.

published disease lifestyle health
Image of article 'Aphria (NASDAQ:APHA) Lifted to “Buy” at BidaskClub'

Aphria (NASDAQ:APHA) Lifted to “Buy” at BidaskClub

The company offers pharmaceutical-grade medical cannabis, adult-use cannabis, and cannabis-derived extracts and derivative cannabis products under the Solei, RIFF, Good Supply, Aphria, P'tite Pof, and Broken Coast brands.

The company reported ($0.10) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.03) by ($0.07).

Separately, Cantor Fitzgerald upped their target price on Aphria from $12.50 to $15.50 and gave the company an overweight rating in a report on Monday, October 5th.

BidaskClub upgraded shares of Aphria (NASDAQ:APHA) from a hold rating to a buy rating in a report published on Tuesday morning, BidAskClub reports.

Receive News & Ratings for Aphria Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aphria and related companies with MarketBeat.com's FREE daily email newsletter.

published earnings business
Image of article 'These Are the World’s 10 Most Sustainably Managed Companies'

These Are the World’s 10 Most Sustainably Managed Companies

The Swiss industrial company placed seventh for employee and workplace issues management within the rankings.

The biotechnology and pharmaceuticals company came in top of the “social capital” ranking, which relates to external social and product issues.

Issues such as access and affordability, which the ranking addresses under the “social capital” heading, are particularly important for companies like Philips, in the medical equipment and supplies industry.

They looked at sustainability metrics including environment, human capital (internal employee and workplace issues), social capital (external social and product issues), and business model and innovation.

The company, which makes materials used for home building, ranked fourth for employee and workplace issues management.

published marketing environment
Image of article 'Pfizer Inc. (NYSE:PFE) Shares Purchased by CX Institutional'

Pfizer Inc. (NYSE:PFE) Shares Purchased by CX Institutional

CX Institutional boosted its stake in shares of Pfizer Inc. (NYSE:PFE) by 310.9% during the third quarter, according to its most recent Form 13F filing with the SEC.

Corbett Road Capital Management LLC acquired a new stake in shares of Pfizer during the 2nd quarter worth approximately $25,000.

Disciplined Investments LLC now owns 1,148 shares of the biopharmaceutical company’s stock worth $37,000 after acquiring an additional 347 shares during the last quarter.

Morgan Stanley lifted their price target on shares of Pfizer from $36.00 to $42.00 and gave the company an “equal weight” rating in a research report on Thursday, July 30th.

In other Pfizer news, Director Ronald E. Blaylock purchased 13,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 6th.

published earnings business
Image of article 'Comparing Matinas BioPharma (MTNB) & Its Rivals'

Comparing Matinas BioPharma (MTNB) & Its Rivals

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates.

Matinas BioPharma is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

13.3% of Matinas BioPharma shares are held by company insiders.

Matinas BioPharma (NYSE: MTNB) is one of 714 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it contrast to its rivals?

Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Neurological Disorders and Stroke (NINDS) for the development of a novel therapy for the treatment of HIV, as well as with ViiV Healthcare to develop and evaluate formulations of antiviral drug candidates; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations.

published pharmaceutical business
Image of article 'Piper Sandler Weighs in on Amneal Pharmaceuticals Inc’s Q3 2021 Earnings (NYSE:AMRX'

Piper Sandler Weighs in on Amneal Pharmaceuticals Inc’s Q3 2021 Earnings (NYSE:AMRX

Finally, Meeder Asset Management Inc. raised its holdings in Amneal Pharmaceuticals by 30.5% in the 1st quarter.

Finally, Zacks Investment Research cut Amneal Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, October 1st.

ValuEngine cut shares of Amneal Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, July 10th.

Amneal Pharmaceuticals Inc (NYSE:AMRX) – Investment analysts at Piper Sandler boosted their Q3 2021 earnings per share (EPS) estimates for Amneal Pharmaceuticals in a research report issued to clients and investors on Thursday, October 8th.

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas.

published earnings business
Image of article 'Analyzing Electromed (ELMD) & Its Competitors'

Analyzing Electromed (ELMD) & Its Competitors

The company offers its products primarily to home health care market for patients with bronchiectasis, cystic fibrosis, and neuromuscular disease.

Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of all ages in the United States and internationally.

19.6% of Electromed shares are held by company insiders.

Electromed (NYSE: ELMD) is one of 59 publicly-traded companies in the “Electromedical equipment” industry, but how does it weigh in compared to its rivals?

Electromed, Inc. markets its products primarily to physicians and health care providers, as well as directly to patients.

published pharmaceutical business
Image of article 'Opthea Announces Launch of Proposed Initial Public Offering in the United States'

Opthea Announces Launch of Proposed Initial Public Offering in the United States

Any statement describing Company goals, expectations, intentions or beliefs, including as they relate to the proposed Offering, is a forward-looking statement and should be considered an at-risk statement.

Forward-looking Statements Certain statements in this ASX announcement may contain forward-looking statements regarding the Company's business as well as the proposed Offering.

About Opthea Opthea (ASX:OPT) is a biopharmaceutical company developing a novel therapy to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).

11, 2020 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progressive retinal diseases, today announces the launch of its initial public offering (the "Offering") of American Depositary Shares ("ADS"), each of which will represent eight of the Company's ordinary shares, in the United States.

Such statements are subject to certain risks and uncertainties, including market conditions and the trading price of the Company's ordinary shares on the ASX.

published chemicals finance
Image of article 'Salarius Pharmaceuticals (NASDAQ:SLRX) Lifted to “Buy” at Zacks Investment Research'

Salarius Pharmaceuticals (NASDAQ:SLRX) Lifted to “Buy” at Zacks Investment Research

Get a free copy of the Zacks research report on Salarius Pharmaceuticals (SLRX) For more information about research offerings from Zacks Investment Research, visit Zacks.com Receive News & Ratings for Salarius Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Salarius Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Salarius Pharmaceuticals, Inc a clinical-stage biotechnology company, develops epigenetic-based cancer treatments.

Bank of New York Mellon Corp purchased a new position in Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) in the first quarter, according to its most recent filing with the Securities & Exchange Commission.

According to Zacks, “Salarius Pharmaceuticals Inc. is a clinical-stage oncology company.

Zacks Investment Research upgraded shares of Salarius Pharmaceuticals (NASDAQ:SLRX) from a hold rating to a buy rating in a research note released on Wednesday morning, Zacks.com reports.

published pharmaceutical business finance
Image of article 'Allena Pharmaceuticals (NASDAQ:ALNA) Stock Rating Lowered by Zacks Investment Research'

Allena Pharmaceuticals (NASDAQ:ALNA) Stock Rating Lowered by Zacks Investment Research

Allena Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally.

LADENBURG THALM/SH SH reiterated a buy rating and set a $8.00 price objective on shares of Allena Pharmaceuticals in a research report on Wednesday, July 15th.

Wedbush reiterated a buy rating and issued a $18.00 price objective on shares of Allena Pharmaceuticals in a report on Thursday, September 10th.

Zacks Investment Research cut shares of Allena Pharmaceuticals (NASDAQ:ALNA) from a buy rating to a hold rating in a research note released on Wednesday morning, Zacks.com reports.

Get a free copy of the Zacks research report on Allena Pharmaceuticals (ALNA) For more information about research offerings from Zacks Investment Research, visit Zacks.com Receive News & Ratings for Allena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

published earnings business

Price Over Earnings Overview: Alexion Pharmaceuticals

The P/E ratio is used by long-term shareholders to assess the company’s market performance against aggregate market data, historical earnings, and the industry at large.

A lower P/E indicates that shareholders do not expect the stock to perform better in the future, and that the company is probably undervalued.

It shows that shareholders are less than willing to pay a high share price, because they do not expect the company to exhibit growth, in terms of future earnings.

Alexion Pharmaceuticals Inc. has a better P/E ratio of 32.84 than the aggregate P/E ratio of 16.56 of the Biotechnology industry.

Ideally, one might believe that Alexion Pharmaceuticals Inc. might perform better in the future than it’s industry group, but it’s probable that the stock is overvalued.

published earnings finance
Image of article 'GlaxoSmithKline: An Unusual Defensive Healthcare Play (NYSE:GSK'

GlaxoSmithKline: An Unusual Defensive Healthcare Play (NYSE:GSK

GSK provides the perfect defensive-growth combination of decent valuation, strong financial position, high dividend yield, and prospects of big upside through product development and M&A activities.

GSK’s share price has been moving in a tight range for years - as is typical with many pharmaceutical mammoths whose revenues and incomes remain stagnated by expiring patents and replacement products.

In addition to the joint venture she created between GSK’s consumer health business and that of US pharma group Pfizer, she also set a three-year timetable for separating the consumer health business from the pharma and vaccine businesses.

The structure of GSK was viewed as distracting to management, especially with the consumer healthcare business not necessarily blending well with the pharma and vaccine businesses.

In both vaccines and consumer healthcare, GSK enjoys leadership positions globally.

published marketing business finance
Image of article 'IPO Update: Codiak BioSciences Proposes IPO Terms (Pending:CDAK'

IPO Update: Codiak BioSciences Proposes IPO Terms (Pending:CDAK

CDAK has developed significant collaboration partnerships with major pharma firms and the IPO appears priced within the typical range for biopharma companies.

The company’s lead drug candidate is exoSTING, an exosome therapeutic for the treatment of solid tumors that is “designed to target [antigen presenting cells] and acts by targeting the small molecule stimulator of interferon genes, or STING pathway, which has been preclinically validated as an attractive target for eliciting an anti-tumor immune response.”

Below is the current status of the company’s drug development pipeline: Investors in Codiak include Yukon Partners, Qatar Investment Authority, Alexandria Venture Investments, ARCH Venture Partners, EcoR1 Capital, Casdin Capital, Alaska Permanent Fund, Sirona Capital, Fidelity Management and Research, and Boxer Capital, among others.

The Asia-Pacific region will grow the fastest, as shown by the graphic below: Industry firms that provide or are developing related treatments include: Codiak’s recent financial results are typical of development stage biopharma firms in that they feature no revenue and significant R&D and G&A expenses associated with advancing its pipeline of treatment programs.

The market opportunity for treating solid tumors is the largest cancer market in the world, and is expected to reach over $400 billion in total size within the decade due to an aging world population and new treatment development.

published pharmaceutical finance business

Head to Head Survey: DiaMedica Therapeutics (NASDAQ:DMAC) vs. HST Global (NASDAQ:HSTC

DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for neurological and kidney diseases.

This table compares DiaMedica Therapeutics and HST Global’s top-line revenue, earnings per share and valuation.

Comparatively, 65.8% of HST Global shares are held by company insiders.

DiaMedica Therapeutics (NASDAQ:DMAC) and HST Global (OTCMKTS:HSTC) are both small-cap medical companies, but which is the superior business?

HST Global, Inc., an integrated health and wellness biotechnology company, develops and/or acquires a network of wellness centers for the homeopathic and alternative treatment of late stage cancer worldwide.

published chemicals business
Image of article 'SUMMIT THERAPEU/S (NASDAQ:SMMT) Announces Quarterly Earnings Results, Misses Expectations By $1.13 EPS'

SUMMIT THERAPEU/S (NASDAQ:SMMT) Announces Quarterly Earnings Results, Misses Expectations By $1.13 EPS

Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat rare and infectious diseases in the United Kingdom and North America.

Separately, Zacks Investment Research downgraded SUMMIT THERAPEU/S from a “hold” rating to a “sell” rating in a research note on Friday.

Shares of SUMMIT THERAPEU/S stock opened at $3.40 on Tuesday.

SUMMIT THERAPEU/S (NASDAQ:SMMT) announced its quarterly earnings data on Sunday.

Receive News & Ratings for SUMMIT THERAPEU/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SUMMIT THERAPEU/S and related companies with MarketBeat.com's FREE daily email newsletter.

published earnings business
Image of article 'MannKind (NASDAQ:MNKD) Cut to “Sell” at BidaskClub'

MannKind (NASDAQ:MNKD) Cut to “Sell” at BidaskClub

UBS Group AG now owns 29,470 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 11,497 shares during the last quarter.

Oppenheimer reiterated a buy rating and set a $2.50 price objective on shares of MannKind in a report on Tuesday, July 14th.

BTIG Research reiterated a buy rating and set a $4.00 price objective on shares of MannKind in a report on Wednesday, June 17th.

BidaskClub lowered shares of MannKind (NASDAQ:MNKD) from a hold rating to a sell rating in a research report report published on Saturday morning, BidAskClub reports.

BNP Paribas Arbitrage SA now owns 63,839 shares of the biopharmaceutical company’s stock worth $66,000 after acquiring an additional 41,316 shares during the last quarter.

published earnings business
Image of article 'IPO Update: Shattuck Labs Proposes Terms For $150 Million IPO (Pending:STTK'

IPO Update: Shattuck Labs Proposes Terms For $150 Million IPO (Pending:STTK

The firm is advancing a pipeline of treatment candidates for ovarian and other cancers.

The company is a clinical stage firm developing treatments for ovarian and other cancers.

Given the IPOs’ reasonable valuation and the firm’s strong collaboration with Takeda, for life science investors with a long-term hold time frame, the IPO is worth a close look.

Below is a brief overview video of the warning signs of ovarian cancer: The firm's lead candidate, SL-172154, is currently in Phase 1 safety trials with ovarian cancer patients and management expects to enter the dose escalation phase of the trial in the second half of 2021.

Major competitive vendors that provide or are developing/funding treatments include: Shattuck’s recent financial results are atypical of an early stage biopharma in that they feature significant collaboration revenue from its partnership with Takeda Pharmaceuticals.

published chemicals finance business